Search clinical trials for: Kepivance

Total 32 results

City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Allogeneic Hematopoietic Stem Cell Transplant Recipient

United States
National Cancer Institute (NCI)

Recruiting

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Acute Leukemia | Myelodysplastic Syndrome

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center

Terminated

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

T-cell Non-Hodgkin Lymphoma

United States
Columbia University

Terminated

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB) (RDEB)

Epidermolysis Bullosa

United States
M.D. Anderson Cancer Center

Completed

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Myeloma

United States
M.D. Anderson Cancer Center

Completed

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

Lymphoma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Lymphoma

United States
Cambridge University Hospitals NHS Foundation Trust

Terminated

Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis (CAM-THY)

Multiple Sclerosis

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hematopoietic Cell Transplantation Recipient

United States
Children's Oncology Group
National Cancer Institute (NCI)

Withdrawn

Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant

Malignant Neoplasm | Gastrointestinal Mucositis
Sherif S. Farag

Terminated

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplasia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Plasma Cell Myeloma | Plasma Cell Leukemia in Remission

United States
Montefiore Medical Center
Nationwide Children's Hospital; Children's Hospital Los Angeles

Terminated

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

Solid Tumor | Allogeneic Hematopoietic Stem Cell Transplantation | Neuroepithelial Tumor

United States
M.D. Anderson Cancer Center

Withdrawn

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Lymphoma
Swedish Orphan Biovitrum
Amgen

Completed

Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Lung Cancer | Dysphagia
Brett King
Swedish Orphan Biovitrum

Terminated

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

Stevens-Johnson Syndrome | Toxic Epidermal Necrolysis

United States
University Hospital Southampton NHS Foundation...

Completed

A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients

Bronchial Asthma

United Kingdom
Swedish Orphan Biovitrum
Amgen

Completed

Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer

Head and Neck Cancer | Mucositis | Stomatitis | Solid Tumors | Squamous Cell Carcinoma
M.D. Anderson Cancer Center

Completed

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

Lymphoma | Leukemia | Myeloma

United States
M.D. Anderson Cancer Center

Completed

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

Lymphoma

United States
Swedish Orphan Biovitrum

Completed

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma

Multiple Myeloma

Germany
Swedish Orphan Biovitrum

Completed

A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT

Leukemia

United States
Swedish Orphan Biovitrum

Completed

Palifermin DDI (Drug Drug Interaction)

Healthy Volunteers
Swedish Orphan Biovitrum

Completed

PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

Multiple Myeloma | Non-Hodgkin's Lymphoma
Swedish Orphan Biovitrum
Amgen

Completed

Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)

Lymphoma | Leukemia | Cancer
Swedish Orphan Biovitrum
Amgen

Completed

Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation

Hematologic Malignancies | Graft Versus Host Disease
M.D. Anderson Cancer Center

Withdrawn

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Myeloma
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Multiple Myeloma | Mucositis

United States
Martin, Paul
National Cancer Institute (NCI)

Completed

Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma and other conditions

United States
European Society for Blood and Marrow Transplantation
Amgen

Withdrawn

Palifermin After Haploidentical PBSCT (KGF Haplo Allo)

Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Acute Leukaemia | Non-Hodgkin's Lymphoma or Hodgkin's Disease | Osteomyelofibrosis

Germany
St. Jude Children's Research Hospital

Completed

Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation | Oral Mucositis

United States

Search clinical trials for: Kepivance

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations